Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a lower dose of a lung cancer drug work just as well with fewer side effects?

NCT ID NCT05037331

Recruiting now Disease control Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a lower dose of the targeted therapy osimertinib can control advanced EGFR-positive non-small cell lung cancer while reducing side effects. About 58 adults with this specific genetic type of lung cancer will receive 80 mg every other day. Researchers will monitor safety, tumor response, and how long the cancer stays under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR POSITIVE NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • National University Hospital

    RECRUITING

    Singapore, Singapore

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.